oonal / iStockphoto.com
Osiris Therapeutics has accused competitor MiMedx of misappropriating trade secrets in a lawsuit filed earlier this week, in which Osiris has demanded more than $6 million in damages.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US District Court for the District of Maryland, MiMedx, Osiris, Stability Biologics, Osiris Ovation, Osiris Grafix, pharmaceutical competition